The Veterans Health Administration, in "an unexpected move," announced Monday that it will widely cover a new Alzheimer’s treatment for veterans who meet agency criteria for using Leqembi, which is being marketed by Eisai (ESALY) and partner Biogen (BIIB), reported STAT’s Ed Silverman. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen Appoints Chuck Triano as Head of Investor Relations
- Biogen price target raised to $350 from $335 at RBC Capital
- Needham healthcare analyst to hold an analyst/industry conference call
- No ad com suggests positive potential outcome for Sage’s zura, says BofA
- Biogen elects Dorsa as Chair of the Board of Directors